Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis

摘要: Biosimilars of granulocyte colony-stimulating factors (G-CSF) have shown similar efficacy to originator filgrastim (Neupogen® [NEU]; Amgen Inc.) as prophylaxis in neutropenia and the mobilization stem cells patients receiving combination chemotherapy with G-CSF. This was a retrospective study which characteristics cell treated G-CSF alone were compared 216 56 donors. The two NEU biosimilar Zarzio® (Sandoz GmbH) (referred hereafter BIO). Primary objectives rate (minimum 10 × 103/ml CD34+ on day 4 treatment [day +4]) use immunostimulant plerixafor (PLEX) each group. general (n = 138) those BIO 78) did not differ significantly. PLEX used 24% 25.7% patients. median CD34+ cell count on +4 significantly lower who needed than (2.4 vs. 4.8 × 103/ml; p 0.002), final (2.5 3.3 × 106/kg; 0.03). Mobilization failure higher group (20 0%; 0.01). With respect donors, more one apheresis three them PLEX. only risk factor for (hazard ratio 10.3; 95% confidence interval 1.3–77.8). revealed that had when G-CSF, especially poor mobilizers needing